



DRUG QUANTITY MANAGEMENT POLICY – PER RX AND PER DAYS

- POLICY:** Infectious Disease – Antiparasitics Drug Quantity Management Policy – Per Rx and Per Days
- albendazole tablets (generic only)
 - Alinia® (nitazoxanide tablets, suspension – Romark, generic for tablets only)
 - Arakoda® (tafenoquine tablets – Sixty Degrees)
 - Benznidazole tablets – Exeltis
 - Coartem® (artemether/lumefantrine tablets – Novartis)
 - Emverm® (mebendazole chewable tablets – Amneal)
 - Impavido® (miltefosine capsules– Profounda)
 - Krintafel (tafenoquine tablets – GlaxoSmithKline)
 - Lampit® (nifurtimox tablets – Bayer HealthCare)
 - Malarone and Malarone Pediatric (atovaquone/proguanil tablets – GlaxoSmithKline, generic)
 - mefloquine tablets (generic only)
 - primaquine phosphate tablets (generic only)
 - Qualaquin® (quinine sulfate capsules – Sun, generic)
 - Stromectol® (ivermectin tablets – Merck, generic)
 - tinidazole tablets (generic only)

REVIEW DATE: 04/23/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

The antiparasitic agents are used in the treatment of various parasitic infections. Drug selection, dose, and duration for treatment and/or prophylaxis are dependent upon the parasite. Table 1 provides drug-specific indications.

Table 1. Antiparasitic Agents Indications.¹⁻¹⁵

Medication	Indication(s)
Albendazole tablets	<ul style="list-style-type: none"> Hydatid Disease caused by <i>Echinococcus granulosus</i> Neurocysticercosis caused by <i>Taenia solium</i>
Alinia (nitazoxanide tablets [generic], suspension)	Diarrhea caused by: <ul style="list-style-type: none"> <i>Giardia lamblia</i> <i>Cryptosporidium parvum</i>
Arakoda (tafenoquine tablets)	Prophylaxis of malaria
Benznidazole tablets	Chagas disease (American trypanosomiasis) caused by <i>Trypanosoma cruzi</i> in patients 2 to 12 years of age.
Coartem (artemether/lumefantrine tablets)	Malaria infections caused by <i>Plasmodium falciparum</i>
Emverm (mebendazole chewable tablets)	Gastrointestinal infections caused by: <ul style="list-style-type: none"> <i>Enterobius vermicularis</i> (pinworm) <i>Trichuris trichiura</i> (whipworm) <i>Ascaris lumbricoides</i> (common roundworm) <i>Ancylostoma duodenale</i> (common hookworm) <i>Necator americanus</i> (American hookworm)

Table 1 (continued). Antiparasitic Agents Indications.¹⁻¹⁵

Medication	Indication(s)
Impavido (miltefosine capsules)	<ul style="list-style-type: none"> Visceral leishmaniasis caused by <i>Leishmania donovani</i> Cutaneous leishmaniasis caused by <i>Leishmania braziliensis</i>, <i>Leishmania guyanensis</i>, <i>Leishmania panamensis</i> Mucosal leishmaniasis caused by <i>Leishmania braziliensis</i>
Krintafel (tafenoquine tablets)	Radical cure of <i>Plasmodium vivax</i> malaria.
Lampit (nifurtimox tablets)	Chagas disease (American Trypanosomiasis), caused by <i>Trypanosoma cruzi</i> in patients < 18 years of age.
Malarone (atovaquone/proguanil tablets, generic)	<ul style="list-style-type: none"> Prophylaxis of <i>Plasmodium falciparum</i> malaria. Treatment of acute, uncomplicated <i>P. falciparum</i> malaria.
Mefloquine tablets	<ul style="list-style-type: none"> Treatment of acute, mild to moderate malaria caused by <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i>. Prophylaxis of <i>P. falciparum</i> or <i>P. vivax</i> malaria.
Primaquine phosphate tablets	Radical cure (prevention of relapse) of malaria infections caused by <i>Plasmodium vivax</i> . The CDC also recognizes primaquine as prophylaxis of malaria for short-duration (not defined) travel to areas with principally <i>P. vivax</i> .
Qualaquin (quinine sulfate capsules, generic)	Treatment of uncomplicated malaria infections caused by <i>Plasmodium falciparum</i> .
Stromectol (ivermectin tablets, generic)	<ul style="list-style-type: none"> Strongyloidiasis of the intestinal tract caused by <i>Strongyloides stercoralis</i> Onchocerciasis caused by <i>Onchocerca volvulus</i>
tinidazole tablets	<ul style="list-style-type: none"> Trichomoniasis caused by <i>Trichomonas vaginalis</i> Giardiasis caused by <i>Giardia lamblia</i> or <i>Giardia duodenalis</i> Amebiasis caused by <i>Entamoeba histolytica</i> Bacterial vaginosis

Dosing

FDA-approved dosing for the antiparasitic agents is provided below. Of note, there may be additional settings in which these agents are recommended. However, if quantity limits provide a sufficient amount of drug to address these uses, information is not provided below.

Albendazole tablets

The dose of albendazole is based on the indication (Table 2).¹ Tablets may be crushed or chewed.

Table 2. Albendazole Dosing.¹

Indication	Patient Weight	Dose	Duration
Hydatid Disease	≥ 60 kg	400 mg BID	28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles
	< 60 kg	15 mg/kg/day given in divided doses twice daily (maximum total daily dose 800 mg)	
Neurocysticercosis	≥ 60 kg	400 mg BID	8 to 30 days
	< 60 kg	15 mg/kg/day given in divided doses twice daily (maximum total daily dose 800 mg)	

In addition to its FDA-approved indications, the Centers for Disease Control (CDC) also recommends albendazole for the treatment of Balisascariasis, an intestinal parasite.¹⁶ When suspicion of Baylisascariasis is high, immediate treatment with albendazole (25 to 50 mg/kg/day for 10 to 20 days) may be appropriate. Albendazole is also recommended as an alternative treatment for Clonorchiasis at a dose of 10 mg/kg/day for 7 days.¹⁷

Nitazoxanide tablets (Alinia, generic) and Alinia suspension

Alinia oral suspension is indicated for patients ≥ 1 year of age, while nitazoxanide tablets are indicated for patients ≥ 12 years of age.⁵ For patients 1 to 3 years of age, the recommended dose of Alinia suspension is 5 mL (100 mg) every 12 hours (Q12H). For patients 4 to 11 years of age, the recommended dose of Alinia suspension is 10 mL (200 mg) Q12H. For patients ≥ 12 years of age the recommended dose is 500 mg Q12H, either as a nitazoxanide 500 mg tablet (Alinia, generic) or 25 mL (500 mg) of Alinia oral suspension. For all patients, the recommended duration of treatment is 3 days.

In addition to its FDA-approved uses, guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with human immunodeficiency virus (HIV) from the CDC, National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA) recommend nitazoxanide 500 mg to 1,000 mg BID for 14 days for the treatment of Cryptosporidiosis in an immunocompromised patient.¹⁸

Arakoda tablets

The recommended dosing for Arakoda is provided in Tables 3 and 4 below. Arakoda can be administered for up to 6 months of continuous dosing.¹²

Table 3. Recommended Dosing for Arakoda.¹²

Regimen	Timing	Dose
Loading	For each of the 3 days before travel to malarious area.	200 mg QD for 3 days.
Maintenance	While in malarious area.	200 mg QW started 7 days after the last loading dose.
Terminal prophylaxis	In the week following exit from malarious state,	200 mg taken one time, 7 days after the last maintenance dose.

QD – Once daily; QW – Once weekly.

Benznidazole tablets

Benznidazole tablets are dosed by body weight (kg).² The recommended dose in pediatric patients (2 to 12 years of age), is 5 mg/kg/day to 8 mg/kg/day administered in two divided doses separated by approximately 12 hours, for a duration of 60 days. Although not indicated in adults, the CDC recognize some adults require treatment for Chagas disease and the dose is 5 mg/kg/day to 7 mg/kg/day in two divided doses for 60 days.^{19,20}

Table 5. Recommended Dosing of Benznidazole Tablets in Pediatric Patients 2 to 12 years of Age.²

Body Weight Range	Dose	Number of 12.5 mg Tablets per Dose	Number of 100 mg Tablets	Duration and Frequency of Therapy
< 15 kg	50 mg	4 tablets	½ tablet	Administered twice daily approximately 12 hours apart for 60 days.
15 kg to < 20 kg	62.5 mg	5 tablets		
20 kg to < 30 kg	75 mg	6 tablets	¾ tablet	
30 kg to < 40 kg	100 mg		1 tablet	
40 kg to < 60 kg	150 mg		1 ½ tablets	
≥ 60 kg	200 mg		2 tablets	

Coartem tablets

For all patients, a 3-day treatment schedule with a total of six doses is recommended.⁷

For adults (≥ 16 years of age) ≥ 35 kg the recommended dose is 4 tablets as an initial dose, then 4 tablets again after 8 hours, and then 4 tablets twice-daily (BID [morning and evening]) for the following 2 days (total course of 24 tablets).⁷

For pediatric patients weighing 5 kg to < 15 kg, the recommended dose is 1 tablet as an initial dose, 1 tablet again after 8 hours, and then 1 tablet BID (morning and evening) for the following 2 days (total course of 6 tablets).⁷ For pediatric patients weighing 15 kg to < 25 kg, the recommended dose is 2 tablets as an initial dose, then 2 tablets again after 8 hours and then 2 tablets BID (morning and evening) for the following 2 days (total course of 12 tablets). For pediatric patients weighing 25 kg to < 35 kg, the recommended dose is 3 tablets as an initial dose, then 3 tablets again after 8 hours and then 3 tablets BID (morning and evening) for the following 2 days (total course of 18 tablets). For pediatric patients weighing ≥ 35 kg, the recommended dose is 4 tablets as a single initial dose, then 4 tablets again after 8

hours, and then 4 tablets BID (morning and evening) for the following 2 days (total course of 24 tablets).

For patients who are unable to swallow the tablets such as infants and children, the tablets may be crushed and mixed with a small amount of water (1 to 2 teaspoons) in a clean container for administration immediately prior to use.⁷ In the event of vomiting within 1 to 2 hours after administration, a repeat dose should be taken. If the repeat dose is vomited, the patient should be given an alternative antimalarial for treatment.

Emverm chewable tablets

The recommended dose for pinworm is 1 tablet one time.⁴ For whipworm, roundworm, and hookworm, the recommended dose is 1 tablet BID (morning and evening) for 3 consecutive days. If the patient is not cured 3 weeks after treatment, a second course of treatment is advised.

In addition to its FDA-approved indications, CDC guidelines support the use of Emverm in the following settings:

- For the treatment of Capillariasis at a dose of 200 mg twice daily (BID) for 20 days.²¹
- For the treatment of Trichinellosis at a dose of 200 mg to 400 mg three times daily (TID) for 3 days, followed by 400 mg to 500 mg TID for 10 days.²²
- For the treatment of Toxocariasis or Visceral Larva Migrants, at a dose of 100 mg to 200 mg BID for 5 days.²³

Impavido capsules

For the FDA-approved indication, the recommended dose of Impavido is 1 capsule (50 mg) BID for patients weighing 30 kg to 44 kg.⁸ In patients weighing ≥ 45 kg the recommended dose is 1 capsule (50 mg) three times daily (TID). For all patients, the treatment duration is 28 days.

Krintafel tablets

The recommended dose is a single, 300 mg dose administered (two 150-mg tablets taken together).¹⁴ Tablets cannot be broken, crushed, or chewed. In the event of vomiting within 1 hour after dosing, a repeat dose should be given. Re-dosing should not be attempted more than once.

Lampit tablets

The dose of Lampit is weight-based (Tables 6 and 7).¹⁵ The recommended dose is taken TID for 60 days. The dose of Lampit is adjusted accordingly if body weight decreases during treatment. Tablets (30 mg and 120 mg tablets) are functionally scored and can be split into one-half (15 mg or 60 mg, respectively) at the scored lines by hand.

Table 6. Total Daily Recommended Dose of Lampit Based on Body Weight.¹⁵

Age	Body Weight Group	Total Daily Dose
Birth to < 18 years of age	≥ 41 kg	8 to 10 mg/kg
	< 41 kg	10 to 20 mg/kg

Table 7. Individual Doses Based on Body Weight in Patients < 18 years of age.¹⁵

Body Weight	Dose	Number of Lampit 30 mg Tablets/Day	Number of Lampit 120 mg Tablets/Day
2.5 kg to 4.5 kg	15 mg	1.5 tablets	--
4.6 kg to < 9 kg	30 mg	3 tablets	--
9 kg to < 13 kg	45 mg	4.5 tablets	--
13 kg to < 18 kg	60 mg	6 tablets	1.5 tablets
18 kg to < 22 kg	75 mg	7.5 tablets	--
22 kg to < 27 kg	90 mg	9 tablets	--
27 kg to < 35 kg	120 mg	12 tablets	3 tablets
35 kg to < 41 kg	180 mg	--	4.5 tablets
41 kg to < 51 kg	120 mg	--	3 tablets
51 kg to < 71 kg	180 mg	--	4.5 tablets
71 kg to < 91 kg	240 mg	--	6 tablets
≥ 91 kg	300 mg	--	7.5 tablets

Atovaquone/proguanil tablets (Malarone, generic)

For the prevention of malaria, prophylactic therapy is started 1 or 2 days before entering a malaria endemic area and continued daily during the stay, and for 7 days after the return.⁹ In adults, the dose is 1 tablet (250 mg/100 mg) per day. For pediatric patients, the dose is based on body weight (Table 8).

Table 8. Dose for Prevention of Malaria in Pediatric Patients.⁹

Body Weight	Total Daily Dose	Dose Regimen
10 to 20 kg	62.5 mg/25 mg	1 pediatric tablet QD
21 to 30 kg	125 mg/50 mg	2 pediatric tablets QD
31 to 40 kg	187.5 mg/75 mg	3 pediatric tablets QD
> 40 kg	250 mg/100 mg	1 adult strength tablet QD

QD – Once daily.

For the treatment of acute malaria, the recommended dose in adults is four tablets (adult strength) as a single daily dose (total daily dose 1 g atovaquone/400 mg proguanil hydrochloride) for 3 consecutive days.⁹ For pediatric patients, the dose is based on weight (Table 9); the duration of therapy is 3 consecutive days.

Table 9. Dose for Treatment of Acute Malaria in Pediatric Patients.⁹

Weight	Total Daily Dose	Dose Regimen
5 to 8 kg	125 mg/50 mg	2 pediatric tablets QD
9 to 10 kg	187.5 mg/75 mg	3 pediatric tablets QD
11 to 20 kg	250 mg/100 mg	1 adult strength tablet QD
21 to 30 kg	500 mg/200 mg	2 adult strength tablets QD
31 to 40 kg	750 mg/300 mg	3 adult strength tablets QD
> 40 kg	1 gram/400 mg	4 adult strength tablets QD

QD – Once daily.

For the prevention or treatment of malaria, in the event of vomiting within 1 hour after dosing, a repeat dose should be taken.⁹

Mefloquine tablets

For the treatment of malaria in adults, the recommended dose is 1,250 mg (5 tablets) as a single dose.¹⁰ For the treatment of malaria in pediatric patients, the recommended dose is 20 to 25 mg/kg. The pediatric dose should not exceed the adult dose. Experience with mefloquine in pediatric patients weighing < 20 kg is limited. If a full-treatment course with mefloquine does not lead to improvement within 48 to 72 hours, mefloquine should not be used for retreatment. An alternative therapy should be used. Similarly, if previous prophylaxis with mefloquine has failed, mefloquine should not be used for curative treatment.

In pediatric patients, if a significant loss of drug product is observed or suspected because of vomiting, a second full dose of mefloquine should be administered to patients who vomit less than 30 minutes after receiving the drug.¹⁰ If vomiting occurs 30 to 60 minutes after a dose, an additional half-dose should be given. If vomiting recurs, the patient should be monitored closely and alternative malaria treatment considered if improvement is not observed within a reasonable period of time.

For the prophylaxis of malaria in adults, the recommended dose is 250 mg (1 tablet) once weekly (QW).¹⁰ In pediatric patients, the recommended dose for the prophylaxis of malaria is 5 mg/kg QW. In pediatric patients weighing > 45 kg, the dose is one 250 mg tablet QW, in pediatric patients weighing 30 to 45 kg the dose is three-quarters of a tablet QW, and in pediatric patients weighing 20 to 30 kg, the dose is one-half tablet QW. Per product labeling, prophylaxis should begin 1 week before arrival in an endemic area. In certain cases, such as when a traveler is taking other medication, it may be desirable to start prophylaxis 2 to 3 weeks prior to departure, in order to ensure that the combination of drugs is well tolerated. The CDC cites prophylaxis should begin \geq 2 weeks prior to arrival and may be started as early as 4 weeks prior to arrival to allow potential adverse events to occur before travel.²⁴ Subsequent weekly doses should be taken regularly, always on the same day of each week.¹⁰ To reduce the risk of malaria after leaving an endemic area, prophylaxis must be continued for 4 additional weeks. When prophylaxis with mefloquine fails, physicians should carefully evaluate which antimalarial to use for therapy.

Primaquine phosphate tablets

The FDA-approved dose for the radical cure of malaria is 1 tablet (26.3 mg) daily (QD) for 14 days.¹¹ The CDC recommends primaquine for prophylaxis for short duration travel (duration not defined) to areas with principally *P. vivax*; the recommended dose is 52.6 mg daily (2 tablets) in adults and 0.8 mg/kg (not to exceed 52.6 mg) in pediatric patients started 1 to 2 days prior to travel, daily while in the malaria endemic area, and daily for 7 days after return from travel.

Quinine sulfate capsules (Qualaquin, generic)

For treatment of uncomplicated malaria in adults, the recommended dose is 648 mg (2 capsules) every 8 hours (Q8H) for 7 days.¹² In patients with severe chronic renal impairment, the recommended dose is a loading dose of 648 mg (2 capsules)

followed 12 hours later by maintenance doses of 324 mg (1 capsule) Q12H for 7 days.

Ivermectin tablets (Stromectol, generic)

The recommended dose of Stromectol for the treatment of strongyloidiasis is a single oral dose designed to provide approximately 200 mcg/kg (Table 10).³ The CDC also cites a two-dose regimen (200 mcg/kg/day for 2 days).²⁵

Table 10. Dosing for Ivermectin for Strongyloidiasis.³

Body Weight	Single Oral Dose Number of 3 mg tablets
15 to 24 kg	1 tablet
25 to 35 kg	2 tablets
36 to 50 kg	3 tablets
51 to 65 kg	4 tablets
66 to 79 kg	5 tablets
≥ 80 kg	200 mcg/kg

The recommended dose for the treatment of onchocerciasis is a single oral dose designed to provide approximately 150 mcg/kg of body weight (Table 11).³ In mass distribution campaigns in international treatment programs, the most commonly used dose interval is 12 months. For the treatment of individual patients, retreatment may be considered at intervals as short as 3 months.

Table 11. Dosing for Ivermectin for Onchocerciasis.³

Body Weight	Single Oral Dose Number of 3 mg tablets
15 to 25 kg	1 tablet
26 to 44 kg	2 tablets
45 to 64 kg	3 tablets
65 to 84 kg	4 tablets
≥ 85 kg	150 mcg/kg

In addition to its FDA-approved indications, CDC guidelines support the use of ivermectin in the following settings:

- For the treatment of Trichuriasis caused by *Trichuris trichiura* (whipworm), at a dose of 200 mcg/kg/day for 3 days.²⁶
- For the treatment of pediculosis, as a single dose of 200 mcg/kg or 400 mcg/kg.²⁷ The dose may be repeated in 9 to 10 days.
- For classic scabies, two doses of oral ivermectin (200 mcg/kg/dose) taken 1 week apart are recommended.²⁸ For crusted scabies, ivermectin 200 mcg/kg/dose should be taken in three doses (Days 1, 2, and 8), five doses (Days 1, 2, 8, 9, and 15), or seven doses (Days 1, 2, 8, 9, 15, 22, and 29).
- For the treatment of hyperinfection syndrome or disseminated strongyloidiasis, at a dose of 200 mcg/kg/day until stool and/or sputum exams are negative for 2 weeks.²⁵

Tinidazole tablets

The recommended dose for trichomoniasis is 2 g as a single dose.⁶ For the treatment of giardiasis in adults, the dose is 2 g as a single dose; in pediatric patients, the dose is 50 mg/kg (up to 2 g) as a single dose. For the treatment of intestinal amebiasis, the recommended dose in adults is a 2 g/day for 3 days. In

pediatric patients the recommended dose is 50 mg/kg/day (up to 2 g/day) for 3 days. For the treatment of amebic liver abscess, the recommended dose in adults is a 2 g/day for 3 to 5 days. In pediatric patients the recommended dose is 50 mg/kg/day (up to 2 g/day) for 3 to 5 days. There are limited pediatric data on durations of therapy exceeding 3 days, although a small number of children were treated for 5 days. For the treatment of bacterial vaginosis, the recommended dose in non-pregnant females is a 2 g/day for 2 days or a 1 g/day for 5 days. For those unable to swallow tablets, tinidazole tablets may be crushed in artificial cherry syrup; four 500 mg tablets can be pulverized and mixed with 10 mL of syrup (final volume of 30 mL).

Availability

Medication	How Supplied
Albendazole tablets	200 mg tablets (bottles of 2 tablets)
Alinia (nitazoxamide tablets [generic], suspension)	500 mg tablets (bottles of 12 or 30 tablets; generic tablets are available in bottles of 6, 12, or 30 tablets) 100 mg/5 mL suspension (60 mL bottle)*
Arakoda (tafenoquine tablets)	100 mg tablets (1 box containing 16 tablets [8 tablets x 1 blister card, 2 blister cards per box])
Benznidazole tablets	12.5 mg tablets (bottles of 100 tablets) 100 mg tablets (bottles of 100 tablets) <u>Note:</u> 100 mg tablets are functionally scored and can be split into one-half (50 mg) or one-quarter (25 mg) to provide doses < 100 mg. 12.5 mg tablets and 100 mg can also be made into a slurry.
Coartem (artemether/lumefantrine tablets)	20 mg/120 mg tablets (bottles of 24 tablets)
Emverm (mebendazole chewable tablets)	100 mg chewable tablet (blister package of 1 tablet)
Impavido (miltefosine capsules)	50 mg capsules (1 carton containing 28 tablets [14 tablets x 1 blister card, 2 blister cards per box])
Krintafel (tafenoquine tablets)	150 mg tablets (unit dose bottles of 2 tablets)
Lampit (nifurtimox tablets)	30 mg tablets (bottles of 100 tablets) 120 mg tablets (bottles of 100 tablets)
Malarone Pediatric (atovaquone/proguanil tablets, generic)	62.5 mg/25 mg tablets (bottles of 100 tablets)
Malarone (atovaquone/proguanil tablets, generic)	250 mg/100 mg tablets (bottles of 100 tablets and unit dose pack of 24 tablets)
Mefloquine tablets	250 mg tablets (blister packs of 1, 10, or 25 tablets and bottles of 25 tablets)
Primaquine phosphate tablets	26.3 mg tablets (equivalent to 15 mg base) [bottles of 100 tablets]
Quaalquin (quinine sulfate capsules, generic)	324 mg capsules (bottles of 30 capsules)
Stromectol (ivermectin tablets, generic)	3 mg tablets (blister card of 20 tablets) 6 mg tablets (blister card of 20 tablets) [generic only]
tinidazole tablets (generic only)	250 mg and 500 mg tablets (250 mg tablets in bottles of 20 and 40 tablets, 500 mg tablets in bottles of 12 and 20 tablets)

* Reconstituted suspension can be stored for 7 days at room temperature, after which any unused portion must be discarded.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of antiparasitic medications. If the Drug Quantity Management rule is not met for the requested product at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below. "One-time" approvals are provided for 30 days in duration.

Drug Quantity Limits

Medication	Retail Maximum Quantity	Home Delivery Maximum Quantity
Albendazole 200 mg tablets	120 tablets per 30 days	360 tablets per 90 days
Alinia (nitazoxanide 500 mg tablets, generic)	12 tablets per 30 days	
Alinia (nitazoxanide 100 mg/5 ml suspension)	180 mL per 30 days	
Arakoda (tafenoquine 100 mg tablets)	32 tablets per 180 days (maximum 16 tablets per dispensing)	
Benznidazole 12.5 mg tablets	720 tablets per 365 days (maximum of 360 tablets per dispensing)	
Benznidazole 100 mg tablets (quantity provided is sufficient for a dose of 8 mg/kg/day for a patient weighing ≤ 150 kg. An override is provided for patients weighing > 150 kg).	720 tablets per 365 days (maximum of 360 tablets per dispensing)	
Coartem (artemether/lumefantrine 20 mg/120 mg tablets)	24 tablets per 30 days	72 tablets per 90 days
Emverm (mebendazole 100 mg chewable tablets)	6 tablets per 30 days	18 tablets per 90 days
Impavido (miltefosine 50 mg capsules)	84 capsules per 30 days	252 capsules per 90 days
Krintafel (tafenoquine 150 mg tablets)	2 tablets per 30 days	6 tablets per 90 days
Lampit (nifurtimox 30 mg tablets)	720 tablets per 180 days (maximum of 360 tablets per dispensing)	
Lampit (nifurtimox 120 mg tablets)	540 tablets per 180 days (maximum of 270 tablets per dispensing)	
Malarone Pediatric (atovaquone/proguanil 62.5 mg/25 mg tablets, generic)	180 tablets per 180 days	
Malarone (atovaquone/proguanil 250 mg/100 mg tablets, generic)	60 tablets per 180 days	
Mefloquine 250 mg tablets	13 tablets per 180 days	
Primaquine phosphate 26.3 mg tablets	120 tablets per 180 days	
Qualaquin (quinine sulfate 324 mg capsules, generic)	42 capsules per 30 days	126 capsules per 90 days
Stromectol (ivermectin 3 mg tablets, generic)	14 tablets per 30 days	42 tablets per 90 days
ivermectin 6 mg tablets (generic only)	8 tablets per 30 days	24 tablets per 90 days
tinidazole 250 mg tablets	40 tablets per 30 days	120 tablets per 90 days
tinidazole 500 mg tablets	20 tablets per 30 days	60 tablets per 90 days

Infectious Disease – Antiparasitics Drug Quantity Management Policy – Per Rx and Per Days product(s) is(are) covered as medically necessary when the following criteria is(are) met. Any other exception is considered not medically necessary.

CRITERIA

Albendazole 200 mg tablets

1. If the request is for the treatment of Baylisascariasis, approve a one-time override for a quantity sufficient to accommodate a dose of up to 50 mg/kg/day for up to 20 days at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 70 kg, the dose would be 3,500 mg per day, divided into two daily doses of approximately 1,700 mg each. A quantity of 18 tablets per day would be needed. Therefore, the total quantity approved would be 360 tablets.
2. If the request is for the treatment of Clonorchiasis, approve a one-time override for a quantity sufficient to accommodate a dose of up to 10 mg/kg/day for 7 days at retail or home delivery.

Nitazoxanide 500 mg tablets (Alinia, generic)

1. If the request is for the treatment of Cryptosporidiosis in an immunocompromised patient (e.g., transplant patients, patients with human immunodeficiency virus), approve a one-time override for the requested quantity, not to exceed 56 tablets at retail or home delivery.

Alinia 100 mg/5 mL suspension

1. If the request is for the treatment of Cryptosporidiosis in an immunocompromised patient (e.g., transplant patients, patients with human immunodeficiency virus), approve a one-time override for the requested quantity, not to exceed 1,400 mL of suspension at retail or home delivery.

Arakoda 100 mg tablets "Per Rx" Limit

No overrides recommended.

Arakoda 100 mg tablets "Per Days" Limit

1. If the patient needs prophylaxis for malaria for > 60 days, approve a one-time override of a quantity sufficient to allow up to 2 tablets daily for 3 days prior to travel to the malaria endemic area (6 tablets), 2 tablets weekly during the stay in the malaria endemic area (2 tablets/week), and 2 tablets taken one time 7 days after return (2 tablets) at retail or home delivery.

Benznidazole 12.5 mg tablets "Per Rx" Limit

No overrides recommended.

Benznidazole 12.5 mg tablets "Per Days" Limit

1. If the patient is diagnosed with a new episode of Chagas disease (American trypanosomiasis) since the last 60-day treatment with benznidazole, approve a

one-time override for the requested quantity, not to exceed 720 tablets at retail or home delivery.

Benznidazole 100 mg "Per Rx" Limit

No overrides recommended.

Benznidazole 100 mg tablets "Per Days" Limit

1. If the patient weighs > 150 kg, approve a one-time override of a quantity sufficient to accommodate a dose of up to 8 mg/kg/day for 60 days at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 170 kg, the dose would be 1,360 mg per day, divided into two daily doses of approximately 680 mg each. Therefore 14 tablets per day for 60 days would be needed. The total approved would be 840 tablets.
2. If the patient is diagnosed with a new episode of Chagas disease (American trypanosomiasis) since the last 60-day treatment with benznidazole, approve a one-time override for the requested quantity, not to exceed 720 tablets at retail or home delivery.

Coartem 20 mg/120 mg tablets

No overrides recommended.

Emverm 100 mg chewable tablets

1. If the request is for the treatment of Capillariasis, approve a one-time override of 80 tablets at retail or home delivery.
2. If the request is for the treatment of Trichinellosis, approve a one-time override for the requested quantity, not to exceed 186 tablets at retail or home delivery.
3. If the request is for the treatment of Toxocariasis or Visceral Larva Migrants, approve a one-time override of 20 tablets at retail or home delivery.

Impavido 50 mg capsules

No overrides recommended.

Krintafel 150 mg tablets

1. If the request is for a repeat dose in a patient who has vomited, approve a one-time override for 2 additional tablets at retail or home delivery.

Lampit 30 mg tablets "Per Rx" Limit

No overrides recommended.

Lampit 30 mg tablets "Per Days" Limit

1. If the patient is diagnosed with a new episode of Chagas disease (American trypanosomiasis) since the last 60-day treatment with Lampit, approve a one-time override for the requested quantity, not to exceed 720 tablets at retail or home delivery.

Lampit 120 mg tablets "Per Rx" Limit

No overrides recommended.

Lampit 120 mg tablets

1. If the patient is diagnosed with a new episode of Chagas disease (American trypanosomiasis) since the last 60-day treatment with Lampit, approve a one-time override for the requested quantity, not to exceed 540 tablets at retail or home delivery.

Atovaquone/proguanil pediatric 62.5 mg/25 mg tablets (Malarone, generic)

1. If the patient weighs ≤ 40 kg and needs prophylaxis for malaria for > 60 days, approve a one-time override of a quantity sufficient to allow up to 3 tablets daily for 2 days before entering a malaria endemic area (6 tablets), up to 3 tablets daily during the stay in the malaria endemic area (3 tablets/day), and 3 tablets daily for 7 days after return (21 tablets) at retail or home delivery.
2. If the request is for a repeat dose in a patient who has vomited, approve a one-time override of up to 3 additional tablets at retail or home delivery.

Atovaquone/proguanil 250 mg/100 mg tablets (Malarone, generic)

1. If the patient weighs > 40 kg and needs prophylaxis for malaria for > 60 days, approve a one-time override of a quantity sufficient to allow up to 1 tablet daily for 2 days before entering a malaria endemic area (2 tablets), 1 tablet daily during the stay in the malaria endemic area (1 tablet/day), and 1 tablet daily for 7 days after return (7 tablets) at retail or home delivery.
2. If the request is for a repeat dose in a patient who has vomited, approve a one-time override up to 4 additional tablets at retail or home delivery.

Mefloquine 250 mg tablets

1. If the patient needs prophylaxis for malaria for > 60 days, approve a one-time override of a quantity sufficient to allow 1 tablet weekly for 4 weeks before entering a malaria endemic area (4 tablets), 1 tablet weekly during the stay in the malaria endemic area (1 tablet/week), and 1 tablet weekly for 4 weeks after return (4 tablets) at retail or home delivery.
2. If the request is for a repeat dose in a patient who has vomited, approve a one-time override of up to 5 additional tablets at retail or home delivery.

Primaquine phosphate 26.3 mg tablets

1. If the patient needs prophylaxis for malaria for > 60 days, approve a one-time override of a quantity sufficient to allow up to 2 tablets daily for 2 days before entering a malaria endemic area (4 tablets), 2 tablets daily during the stay in the malaria endemic area (2 tablets/day), and 2 tablets daily for 7 days after return (14 tablets) at retail or home delivery.

Quinine sulfate 324 mg capsules (Qualaquin, generic)

No overrides recommended.

Ivermectin 3 mg tablets (Stromectol, generic)

1. If the request is for the treatment of Trichuriasis caused by *Trichuris trichiura* (whipworm), approve a one-time override of a quantity sufficient to accommodate a dose of 200 mcg/kg/day for 3 days at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 70 kg, the dose would be 14 mg per day. Therefore 5 tablets per day for 3 days would be needed. The total approved would be 15 tablets.
2. If the request is for pediculosis, approve a one-time override of a quantity sufficient to accommodate a dose of up to 400 mcg/kg/day (1 dose) for two doses at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 70 kg, the dose would be 28 mg per dose. Therefore 10 tablets per dose for 2 doses would be needed. The total approved would be 20 tablets.
3. If request is for the treatment of scabies, approve a one-time override of a quantity sufficient to accommodate a dose of 200 mcg/kg/dose for up to 7 doses at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 70 kg, the dose would be 14 mg per dose. Therefore, 5 tablets per dose for 7 doses would be needed. The total approved would be 35 tablets.
4. If the request is for hyperinfection syndrome or disseminated strongyloidiasis, approve a one-time override for a quantity sufficient to accommodate a dose of 200 mcg/kg/day until stool and/or sputum exams are negative for 2 weeks at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 70 kg, the dose would be 14 mg per day. Therefore, 5 tablets per day would be needed.
5. If the patient weighs > 100 kg, approve a one-time override of a quantity sufficient to accommodate a dose of 200 mcg/kg/day for 2 days at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 120 kg, the dose would be 24 mg per dose. Therefore, 8 tablets per day for 2 days would be needed. The total approved would be 16 tablets.

Ivermectin 6 mg tablets (generic only)

1. If the request is for the treatment of Trichuriasis caused by *Trichuris trichiura* (whipworm), approve a one-time override of a quantity sufficient to accommodate a dose of 200 mcg/kg/day for 3 days at retail or home delivery.
Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 80 kg, the dose would be 16 mg per day, rounded up to 18 mg per day. Therefore 3 tablets per day for 3 days would be needed. The total approved would be 9 tablets.
2. If the request is for pediculosis, approve a one-time override of a quantity sufficient to accommodate a dose of up to 400 mcg/kg/day (1 dose) for two doses at retail or home delivery.

Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 70 kg, the dose would be 28 mg per dose, rounded up to 30 mg. Therefore 5 tablets per dose for 2 doses would be needed. The total approved would be 10 tablets.

3. If request is for the treatment of scabies, approve a one-time override of a quantity sufficient to accommodate a dose of 200 mcg/kg/dose for up to 7 doses at retail or home delivery.

Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 90 kg, the dose would be 18 mg per dose. Therefore, 3 tablets per dose for 7 doses would be needed. The total approved would be 21 tablets.

4. If the request is for hyperinfection syndrome or disseminated strongyloidiasis, approve a one-time override for a quantity sufficient to accommodate a dose of 200 mcg/kg/day until stool and/or sputum exams are negative for 2 weeks at retail or home delivery.

Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 90 kg, the dose would be 18 mg per day. Therefore, 3 tablets per day would be needed.

5. If the patient weighs > 120 kg, approve a one-time override of a quantity sufficient to accommodate a dose of 200 mcg/kg/day for 2 days at retail or home delivery.

Note: Round up to the nearest whole tablet per dose when calculating the approved quantity. For example, if a patient weighs 150 kg, the dose would be 30 mg per dose. Therefore, 5 tablets per day for 2 days would be needed. The total approved would be 10 tablets.

Tinidazole 250 mg and 500 mg tablets

No overrides recommended.

REFERENCES

1. Albendazole tablets [prescribing information]. North Wales, PA: Teva; July 2019.
2. Benznidazole tablets [prescribing information]. Florham Park, NJ: Exeltis; March 2025.
3. Stromectol® tablets [prescribing information]. Whitehouse Station, NJ: Merck; November 2024.
4. Emverm® chewable tablets [prescribing information]. Bridgewater, NJ: Amneal; August 2021.
5. Alinia® tablets and suspension [prescribing information]. Tampa, FL: Romark; March 2024.
6. Tindamax tablets [prescribing information]. San Antonio, TX: Mission; December 2021.
7. Coartem® tablets [prescribing information]. East Hanover, NJ: Novartis; November 2024.
8. Impavido® capsules [prescribing information]. Orlando, FL: Profounda; March 2025.
9. Malarone and Malarone Pediatric tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2023.
10. Mefloquine tablets [prescribing information]. North Wales, PA: Teva; February 2023.
11. Primaquine phosphate tablets [prescribing information]. Short Hills, NJ: Bayshore; January 2024.
12. Qulaquin® capsules [prescribing information]. Cranbury, NJ: Sun; June 2019.
13. Arakoda™ tablets [prescribing information]. Washington, DC: Sixty Degrees; January 2025.
14. Krintafel® tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2023.
15. Lampit tablets [prescribing information]. Whippany, NJ: Bayer HealthCare; December 2024.
16. Centers for Disease Control and Prevention. Clinical Treatment of Raccoon Roundworm: Balisascaris infection. Last reviewed: November 5, 2024. Available at: <https://www.cdc.gov/baylisascaris/hcp/clinical-care/index.html>. Accessed on April 15, 2025.

17. Centers for Disease Control and Prevention. Clinical Overview of Clonorchis. . Last reviewed: February 12, 2024. Available at: https://www.cdc.gov/liver-flukes/hcp/clinical-overview-clonorchis/?CDC_AAref_Val=https://www.cdc.gov/parasites/clonorchis/health_professionals/index.html. Accessed on April 15, 2025.
18. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Last reviewed: January 10, 2024. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new>. Accessed April 15, 2025.
19. Bern C, Montgomery SP, and Herwaldt BL. Evaluation and treatment of Chagas disease in the United States. Sytematic review. *JAMA*. 2007;298(18):2171-2181.
20. Centers for Disease Control and Prevention. Clinical Care of Chagas Disease.. Last updated February 2, 2024. Available at: <https://www.cdc.gov/chagas/hcp/clinical-care/index.html>. Accessed on April 15, 2025.
21. Centers for Disease Control and Prevention. Clinical Care of Capillariasis. Last updated February 16, 2024. Available at: <https://www.cdc.gov/capillaria/hcp/clinical-care/>. Accessed on April 15, 2025.
22. Centers for Disease Control and Prevention. Clinical Care of Trichinellosis. Last updated March 12, 2024. Available at: <https://www.cdc.gov/trichinellosis/hcp/clinical-care/index.html>. Accessed on April 15, 2025.
23. Centers for Disease Control and Prevention. Clinical Care of Toxocariasis. Last updated April 15, 2025. Available at: <https://www.cdc.gov/toxocariasis/hcp/clinical-care/index.html>. Accessed on April 15, 2025.
24. Centers for Disease Control and Prevention. Traveler's health. Travel-related infectious diseases. Malaria. Last reviewed January 30th, 2025. Available at: <https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria#1939>. Accessed on April 15, 2025.
25. Centers for Disease Control and Prevention. Clinical Care of Strongyloides. Last updated February 16, 2024. Available at: <https://www.cdc.gov/strongyloides/hcp/clinical-care/index.html>. Accessed on April 15, 2025.
26. Centers for Disease Control and Prevention. Clinical Care of Soil-transmitted Helminths. Last updated June 3, 2024. Available at: <https://www.cdc.gov/sth/hcp/clinical-care/index.html>. Accessed on April 16, 2025.
27. Centers for Disease Control and Prevention. Clinical Care of Head Lice. Last updated January 31, 2025. Available at: <https://www.cdc.gov/lice/hcp/clinical-care/index.html>. Accessed on April 16, 2025.
28. Centers for Disease Control and Prevention. Clinical Care of Scabies. Last updated December 18, 2023. Available at: https://www.cdc.gov/parasites/scabies/health_professionals/meds.html. Accessed on April 16, 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery. Albedazole 200 mg tablets (Albenza, generic): Brand Albenza removed from policy (obsolete for > 3 years). Generics remain in policy. Alinia 100 mg/5 mL suspension): Quantity limits changed to 180 mL per 30 days at retail or home delivery. Previously, quantity limits were 360 mL per 30 days at retail or 1,080 mL per 90 days at home delivery.	05/31/2023
Annual Revision	Throughout override criteria, notes in reference to recommended dosing were removed and the information moved to the Overview section of the policy. Throughout override criteria, notes were added to provide examples of how to calculate tablet/capsule amounts for drugs with weight-based dosing.	06/05/2024

	<p>Mefloquine 250 mg tablets: Override criteria were updated to provide a quantity sufficient to allow 1 tablet weekly for 4 weeks before entering a malaria endemic area (4 tablets), 1 tablet weekly during the stay in the malaria endemic area (1 tablet/week), and 1 tablet weekly for 4 weeks after return (4 tablets) at retail or home delivery. Previously, criteria approved a quantity sufficient to allow 1 tablet weekly for 3 weeks, 1 tablet weekly during the stay in the malaria endemic area (1 tablet/week), and 1 tablet weekly for 4 weeks after return (4 tablets) at retail or home delivery.</p>	
Annual Revision	<p>The title of the policy was updated to "Infectious Disease - Antiparasitics Drug Quantity Management Policy – Per Rx and Per Days". Previously, the policy name was "Infectious Disease - Antiparasitics Drug Quantity Management Policy – Per Days".</p> <p>The Policy Statement was clarified to state that "one-time" approvals are provided for 30 days in duration.</p> <p>Arakoda 100 mg tablets: Override criteria were clarified to note they apply to the "Per Days" limit. There are no overrides to the "Per Rx" limit.</p> <p>Benznidazole 12.5 mg and 100 mg tablets: Override criteria were clarified to note they apply to the "Per Days" limit. There are no overrides to the "Per Rx" limit. "Per Days" override criteria were clarified to approve for the requested quantity, not to exceed 720 tablets at retail or home delivery. Previously, criteria approved up to 720 tablets as a 60-day supply at retail or home delivery.</p> <p>Lampit 120 mg tablets: Override criteria were clarified to note they apply to the "Per Days" limit. There are no overrides to the "Per Rx" limit. "Per Days" override criteria were clarified to approve for the requested quantity, not to exceed 540 tablets at retail or home delivery. Previously, criteria approved the requested quantity, not to exceed 540 tablets as a 60-day supply at retail or home delivery.</p> <p>Atovaquone/proguanil pediatric 62.5 mg/25 mg tablets (Malarone, generic) and atovaquone/proguanil 250 mg/100 mg tablets (Malarone, generic): Override criteria for a repeat dose in a patient who has vomited were clarified to approve up to 3 additional tablets. Previously, these criteria approved up to 3 tablets.</p> <p>Mefloquine 250 mg tablets: Override criteria for a repeat dose in a patient who has vomited were clarified to approve up to 5 additional tablets. Previously, these criteria approved up to 5 tablets.</p> <p>Ivermectin 6 mg tablets (generic only): New quantity limits of 8 tablets per 30 days at retail and 24 tablets per 90 days at home delivery were added. The following override criteria were added:</p> <ul style="list-style-type: none"> • A one-time override for a quantity sufficient to accommodate a dose of 200 mcg/kg/day for 3 days at retail or home delivery, if the request is for the treatment of Trichuriasis caused by <i>Trichuris trichiura</i> (whipworm). • A one-time override for a quantity sufficient to accommodate a dose of up to 400 mcg/kg/day (1 dose) for two doses at retail or home delivery, if the requested is for pediculosis. • A one-time override for a quantity sufficient to accommodate a dose of 200 mcg/kg/dose for up to 7 doses at retail or home delivery, if the request is for the treatment of scabies. • A one-time override for a quantity sufficient to accommodate a dose of 200 mcg/kg/day until stool and/or sputum exams are negative for 2 weeks at retail or home delivery, if the request is for hyperinfection syndrome or disseminated strongyloidiasis. • A one-time override for a quantity sufficient to accommodate a dose of 200 mcg/kg/day for 2 days at retail or home delivery, if the patient weighs > 120 kg. 	04/23/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.